RHRahat Hadi

Rahat Hadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rahat Hadi has a total of 157 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dynamics of cell-free DNA in predicting response in adult diffuse glioma on chemoradiotherapy

    by Adil Husain, Sridhar Mishra, Rahat Hadi, Avnish Sahu, Swati Kumari, Madhup Rastogi, Rohini Khurana, Saumya Shukla, Mohammed Haris Siddiqui, Nuzhat Husain


  • Polymorphism in cytochrome P4502A6 reduces the risk to head and neck cancer and modifies the treatment outcome

    by Vinay Kumar Yadav, Tridiv Katiyar, Munindra Ruwali, Sanjay Yadav, Sudhir Singh, Rahat Hadi, Madan Lal Brahma Bhatt, Devendra Parmar

    The present case-control study consisting of 1300 cases of head and neck squamous cell carcinoma (HNSCC) and the equal number of controls aimed to investigate the association of functionally important polymorphisms in cytochrome P4502A6 (CYP2A6*1B, CYP2A6*4C, CYP2A6*9-rs28399433) with HNSCC and the treatment response in cases receiving a combination of chemo-/radiotherapy. A significant decrease in risk to HNSCC was observed in the cases with deletion (CYP2A6*4B and CYP2A6*4C) or reduced activity genotypes (CYP2A6*9) of CYP2A6. This risk to HNSCC was further reduced significantly in tobacco users among the cases when compared to non-tobacco users among the cases. The risk was also reduced to a slightly greater extent in alcohol users among the cases when compared to non-alcohol users among the cases. In contrast with decreased risk to HNSCC, almost half of the cases with variant genotypes of CYP2A6 (CYP2A6*1A/*4C+*1B/*4C+*4C/*4C and *9/*9) did not respond to the treatment. Likewise, the survival rate in cases receiving the treatment, after 55 months of follow-up was significantly lower in cases with deletion (6.3%) or reduced activity (11.9%) allele than in the cases with common alleles (41%). The present study has shown that CYP2A6 polymorphism significantly reduces the risk to HNSCC. Our data further suggested that CYP2A6 polymorphism may worsen the treatment outcome in the cases receiving chemo-/radiotherapy.


  • Dosimetric comparison of 3-dimensional conformal radiotherapy (3D-CRT) and volumetric-modulated arc therapy (VMAT) in locally advanced cancer cervix

    by Animesh Agrawal, Rahat Hadi, Satyajeet Rath, Avinav Bharati, Madhup Rastogi, Rohini Khurana, Kamal Sahni, Shantanu Sapru, Ajeet Kumar Gandhi, Anoop Kumar Srivastava, et al.

    Introduction:Dosimetric advantages of volumetric-modulated arc therapy (VMAT) over three-dimensional conformal radiotherapy (3D-CRT) are not established in a head-on comparison of a uniform group of locally advanced carcinoma of the cervix (LACC). Therefore, we conducted a dosimetric comparison of these two techniques in LACC patients.Materials and methods:Computed tomography (CT) data of histologically proven de novo LACC, including Stage IIB–IIIB and earlier stages deemed inoperable, were included in this prospective observational dosimetric study. Planning was initially done by 3D-CRT technique (dose of 45–50·4 Gy @ 1·8–2 Gy/# was used in the actual treatment), followed by VMAT planning and appropriate dosimetric comparisons were done in 39 cases.Results:For planning target volume coverage, D95, D98 and D100 (p < 0·0001 for all parameters) and V95 and V100 (p = 0·002 and <0·0001, respectively) were significantly improved with VMAT. The conformity index (CI) was significantly better with VMAT (p = 0·03), while 3D-CRT had a significantly better homogeneity index (HI)(p = 0·003). Dose to the urinary bladder was significantly reduced with VMAT compared to 3D-CRT for V20–V50, except V10. The doses to the rectum and abdominal cavity were significantly reduced with VMAT compared to 3D-CRT plans for all parameters (V10–V50). The number of organs at risks (OARs) for which constraints were met was higher with VMAT plans than with 3D-CRT plans, with at least four out of the five OARs protected in 46·1 versus 5·1% and all constraints achieved in 15·4% versus none.Conclusion:We conclude that in dosimetric terms, VMAT is superior to 3D-CRT for LACC.


  • Island Nasolabial Flap for Tongue Reconstruction: Locoregional Flap of Choice and an Alternative to Free Flap for Tongue Cancer

    by Vikas Sharma, Sandhya Pandey, Ajeet Kumar Gandhi, Arun Pandey, Madhup Rastogi, Rohini Sethi, Rahat Hadi, Nuzhat Hussain

    Reconstruction following excision for tongue cancer carries important functional consequences. Island nasolabial flap (NLF) is robust and oncologically safe and has a good functional outcome, identical to free flap reconstruction. We retrospectively analyzed the data of 11 tongue cancer patients operated between January 2019 and August 2019. Surgical resection and neck dissection followed by immediate reconstruction by island NLF were done. Post-operative functional outcome assessed using the University of Washington Quality of Life Questionnaire. Age of patients ranged between 39 and 70 years. All patients had either T2 or T3 tongue cancer. No incidence of flap necrosis noted in any patient. On an average, all were discharged between 3rd and 5th post-operative days. Cosmetic and functional outcomes were satisfactory in all patients. Island nasolabial has an excellent reach and can reach any part of the oral cavity, even to the contralateral side and base of the tongue. It has an excellent post-operative tongue function, almost equivalent to free flap. Hence, it should be considered locoregional flap of choice for tongue reconstruction.


  • Open Access

    Evaluation of the effect of random setup errors on dose delivery in Intensity Modulated Radiotherapy

    by Avinav Bharati, Susama Rani Mandal, Anoop Kumar Srivastava, Madhup Rastogi, Rohini Khurana, Rahat Hadi, Shantanu Sapru, Ajeet Kumar Gandhi, S.P. Mishra

    Aim: To conduct a study on the effect of random setup errors inpatient for dose delivery in Intensity Modulated Radiotherapy plans using Octavius 4D phantom. Materials and methods: 11 patients with cancer of H&N were selected for this study. An IMRT plan was created for each patient. The IMRT quality assurance plans were transferred to Mosaiq workstation in a linear accelerator. These plans were delivered at the reference treatment position. Subsequently, the QA plans were delivered on the Octavius 4D phantom after introducing errors in various translational and rotational directions. The setup inaccuracies introduced varied from 1 mm to 5 mm along X, Y. These setup uncertainties were then introduced along X and Y direction simultaneously in equal measures. Similarly, IMRT plans were delivered also after introducing roll and yaw rotation of 1, 2 and 3 degrees in phantom. The deviation of gamma indices at all these positions was analyzed with respect to the reference setup position. Results: The percentage of points passing the gamma acceptance criterion decrease as we increase the setup error. The change is found to be very insignificant with setup error up to 2 mm along X, Y or XY direction. Similarly, the rotational error of up to 3 degrees is found to be acceptable. Conclusions: Small setup (< 2 mm) correction in patients may not adversely affect the dose delivery. But an error of similar magnitude in 2 directions simultaneously has a much greater impact on IMRT dose delivery.


  • Open Access

    The Role of Circulating Tumour DNA as a Marker of Adequate Resection in Oral Cancer and its Correlation with Clinicopathologic Parameters: A Prospective Study

    by Akhlak Husain, Ashish Singhal, Akash Agarwal, Rahat Hadi, Nuzhat Husain

    Introduction: Oral Cavity Squamous Cell Carcinoma (OSCC) is prevalent worldwide. The genetic heterogeneity of this disease and the limitation of biopsy in selective mapping, made use of conventional biopsy suboptimal for advanced molecular profiling. There is a lacuna for non-invasive tests which are easy to perform, helpful in diagnosis, follow-up and in analysing the completeness of treatment, Sensitive and specific detection of circulating tumour DNA (ctDNA) has potential to direct early treatment and permits monitoring of systemic dissemination. Aim: To evaluate ctDNA as response assessment tool and as a clinicopathological parameter. Materials and Methods: This prospective study of 25 patients, carried out at Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh India, from May 2017 to November 2018, The study evaluated ctDNA as a marker of completeness of resection after upfront surgery for OSCC. ctDNA levels were assessed in peripheral blood, before and after surgery to determine whether its quantification can be useful in evaluation of response to surgery and if circulating DNA levels correlate with clinic-pathological prognostic variables. Data analysis was done using Cox proportional model with univariate and multivariate analysis. Results: The ctDNA levels were higher among the patient with age <= 40, females, short duration of disease months), infiltrative variety of tumours and lower tumour volume. The levels increase with increase in mitotic index, lymphocytic infiltrate, tumour budding and decrease with the amount of necrosis, and dysplasia but none reached statistical significance. The level of pre-operative ctDNA does not vary widely with margin status, with treatment and do not correlate with the percentage of positive nodes among the total number of nodes dissected. The cases with local recurrence or death had higher pre-operative ctDNA values (Mean pre-operative ctDNA were 294.725 and 185,6, respectively, with a p-value 0.3673), Conclusion: The ctDNA levels are persistently elevated in OSCC and may be a measure of aggressiveness. The surgical treatment of resectable oral cavity cancers may lead to the decrease of ctDNA levels. ctDNA maybe uses as a complementary method along with biopsy/histopathological findings.


  • Interaction of glutathione‐s‐transferase genotypes with environmental risk factors in determining susceptibility to head and neck cancer and treatment response and survival outcome

    by Tridiv Katiyar, Vinay Yadav, Shailendra S. Maurya, Munindra Ruwali, Madhu Singh, Feza Hasan, Rahul Pandey, Divya Mehrotra, Sudhir Singh, Shambhavi Mishra, et al.

    The present case‐control study aimed to investigate the role of interaction of glutathione‐s‐transferase (GST) genotypes with environmental risk factors in determining susceptibility to head and neck squamous cell carcinoma (HNSCC) involving 1,250 cases and equal number of healthy controls. An increase in the risk of HNSCC and its subsites (larynx, pharynx, and oral cavity) was observed among the cases with null genotypes of GSTM1 (odds ratio [OR] = 1.87) or GSTT1 (OR = 1.39) while reduced risk (OR = 0.81) was observed the cases with variant genotype of GSTP1. Tobacco use in the form of smoking or chewing interacted multiplicatively with GSTM1 or GSTT1 to increase the risk several folds (3–10 folds) in HNSCC and its subsites. Alcohol use also increased the risk (2–3 folds) to HNSCC and its subsites in cases with null or variant genotypes of GSTs, though this risk was of lesser magnitude when compared to the tobacco users. A synergistic effect of both, tobacco smoking and alcohol drinking, led to several folds (25‐folds) increased risk to HNSCC among the cases with null genotype of GSTM1 and GSTT1 when compared to nonsmokers and nondrinkers with wild genotype of GSTM1 and GSTT1 in controls. Furthermore, cases with variant genotypes of GSTP1 (Val/Val) showed superior treatment response with improved survival rate and lower risk of death when compared to the patients with wild type genotype (Ile/Ile). The data suggest that though polymorphism in GSTs may be a modest risk factor for determining HNSCC risk, gene‐environment interactions significantly modify the susceptibility to HNSCC by several folds.


  • Treatment Pattern and Outcomes in Verrucous Carcinoma of Oral Cavity: A Single Institutional Retrospective Analysis from a Tertiary Cancer Center and Review of Literature

    by Satyajeet Rath, Ajeet Kumar Gandhi, Madhup Rastogi, Akash Agarwal, Ashish Singhal, Vikash Sharma, Rohini Khurana, Harikesh Bahadur Singh, Sambit Swarup Nanda, Rahat Hadi, et al.


  • Open Access

    Kirsten rat sarcoma virus protein overexpression in adenocarcinoma lung: Association with clinicopathological and histomorphological features

    by Rahat Hadi, Rahul Kumar Pandey, Saumya Shukla, Nuzhat Husain, Mohammad Hayatul Islam, Ashish Singhal, Surya Kant Tripathi, Rajiv Garg

    Context: Lung cancer is the leading cause of cancer-related deaths worldwide. The constitutive activation of multiple signaling pathways is the major cause of carcinogenesis. Aims: The study evaluates the frequency of Kirsten rat sarcoma virus (KRAS) protein overexpression and correlates with clinicopathological and histomorphological features in non-small cell lung carcinoma (NSCLC)-adenocarcinoma. Settings and Design: Tertiary hospital-based retrospective and prospective case series included 100 cases of NSCLC-adenocarcinoma. Materials and Methods: The basic panel of Immunohistochemistry including Napsin-A, thyroid transcription factor-1 (TTF-1), and markers for squamous differentiation, p-40 was used in formalin-fixed paraffin-embedded tissue blocks. The KRAS monoclonal antibody (9.13, Thermo Fisher Scientific, USA) was used. Statistical Analysis Used: The IBM-Statistical Package for the Social Sciences (SPSS) (SPSS, International Business Machines Corporation, New York, NY, USA) analysis software, version 16 was used for all statistical calculations. Results: KRAS protein expressed in 28.0% (28/100) cases. Cases were grouped as KRAS positive and negative. TTF-1 and Napsin-A were expressed in 89.25% (n = 25) and 92.86% (n = 26) cases, respectively. Stage IV clinical disease was identified in 55% of cases, and 36.84% of cases had a mean survival between 6 and 12 months. In KRAS positive group, the most common pattern of cellular arrangement was acinar/loose clusters pattern present in 64.29% (n = 21) and 75.0% (n = 18) cases followed by the solid pattern present in 42.86% of cases (n = 12), respectively. Necrosis was identified in 57.14% (n = 16) cases. Mucin pattern was present in 32.14% of cases (n = 9), which was significantly different when compared with the KRAS negative group (P = 0.036). Conclusions: This finding may imply that KRAS mutations may not be entirely triggered by alterations induced by carcinogens in smoke. KRAS gene is frequently mutated in pulmonary tumors. It should be tested in NSCLC owing to its predictive and prognostic effects.